EUVIMEDSkopri EUVIMED
CrossrefKarta ta’ informazzjoni

Histiocytosis X or Langerhans’ Cell Histiocytosis – Evaluation, Treatment and Prognosis

I. Haas, A. Donner

Oto-Rhino-Laryngologia Nova · 1998

DOI: 10.1159/000027814 ↗
AstrattDettalji biblijografiċi

Astratt

Objectives: The pathology and the extreme clinical varieties of this disease with emphasis on head and neck manifestations are discussed. Material: A case of Langerhans’ cell histiocytosis (LCH) with extensive destruction of temporal bones is presented. Results and Conclusions: LCH or histiocytosis X embraces a group of rare, mainly pediatric disorders of disputable nature. Granulomatous lesions can be detected in one (unifocal) or multiple organs or tissues (multifocal) with extreme clinical variety from self-healing monostotic lesions to multisystemic life-threatening disease. Lesions typically consist of dendritic antigen-presenting Langerhans’ cells, eosinophilic granulocytes, lymphocytes, ordinary histiocytes, foam cells and multinucleated giant cells. No histopathologic criteria exist in regard to prognosis. Unpredictable behavior of LCH also defies a convenient clinical classification, but number of lesions, vital organ involvement and dysfunction seem to be prognostically and thus therapeutically relevant. Although proof of monoclonality indicates a true neoplastic process, no prognostic use results so far since clonality has been detected in all forms of LCH.

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.

Ara t-tariffi →